Table 1 Demographic and clinical characteristics of study participants
Patients with PD | N = 33 |
|---|---|
Demographic characteristics | |
Sex assigned at birth (M/F) | 24/9 |
Age (years), mean ± STD (min-max) | 64.3 ± 7.7 (48–77) |
Languages, n (%) | |
- Swiss-German | 21 (63.7%) |
- French | 8 (24.2%) |
- Italian | 4 (12.1%) |
Disease duration (years) ± STD, (min-max) | 10.3 ± 3.4 (3.0–18.0) |
Clinical characteristics, mean ± STD (min-max) | |
MDS-UPDRS I | 12.8 ± 5.8 (2.0–28.0) |
MDS-UPDRS II | 15.5 ± 6.8 (2.0–26.0) |
MDS-UPDRS III: OFF medication | 44.1 ± 12.0 (24.0–73.0) |
MDS-UPDRS III: ON medication | 19.7 ± 7.3 (7.0–38.0) |
MDS-UPDRS IV | 10.5 ± 3.9 (0.0–17.0) |
Neuropsychiatric State Score: ON medication | 48.2 ± 8.7 (26.0–60.0) |
Neuropsychiatric State Score: OFF medication | 17.2 ± 12.0 (0.0–49.0) |
QUIP-RS | 9.9 ± 11.3 (0.0–41.0) |
SAS | 10.5 ± 4.2 (3.0–19.0) |
HADS -Anxiety | 5.9 ± 3.9 (0.0–15.0) |
HADS-Depression | 4.2 ± 3.0 (0.0–16.0) |
MoCA | 25.9 ± 2.7 (20–30) |
Average Speech Length (seconds) | 44.8 ± 14.9 (15.2–106) |
Speech length in ON medication | 43.7 ± 11.8 (15.2-76.7) |
Speech length in OFF medication | 45.9 ± 17.6 (17.1-106) |
